We observed that 1) SGLT-2 inhibitors reduced the risk of hospitalization for HF; 2) SGLT-2 inhibitors reduced NT-proBNP levels; and 3) SGLT-2 inhibitors improved exercise capacity and QOL. This evidence concerns the gene NPPB and hydrops fetalis.